Plasma Pentraxin3 and Arterial Stiffness in Men With Obstructive Sleep Apnea

Kasai, Takatoshi; Inoue, Kenji; Kumagai, Takiko; Kato, Megumi; Kawana, Fusae; Sagara, Mina; Ishiwata, Sugao; Ohno, Minoru; Yamaguchi, Tetsu; Momomura, Shin‐ichi; Narui, Koji

doi:10.1038/ajh.2010.248

Cited by 61 publications

(64 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, our results also revealed that waist circumference, CRP and CAVI only are independent determinants of the AHI values in obese patients. Our data correspond to the findings of a report that revealed that the levels of pentraxin 3 and CRP, inflammatory markers, are higher in patients with moderate-tosevere OSA than in patients without OSA and are correlated with higher CAVI values 25) . These results suggest that low-grade systemic inflammation is a key mediator linking obesity-MetS-OSA and may be contribute to the progression of atherosclerosis.…”

Section: Effects Of Body Weight Reduction On Metabolic Parameters Casupporting

confidence: 77%

Effects of Weight Reduction Therapy on Obstructive Sleep Apnea Syndrome and Arterial Stiffness in Patients with Obesity and Metabolic Syndrome

Iguchi

Tochiya

Muranaka

et al. 2013

JAT

View full text Add to dashboard Cite

Aim: Obesity and metabolic syndrome (MetS) and obstructive sleep apnea (OSA), which are often accompanied by obesity, are each independently associated with cardiovascular disease (CVD). However, the influence of OSA on arterial stiffness in obese patients remains unclear. We herein examined the relationships between the severity of OSA and CVD risk factors, including the severity of MetS and arterial stiffness, in obese patients. In addition, we evaluated the effects of weight reduction therapy on OSA and arterial stiffness.

show abstract

Section: Effects Of Body Weight Reduction On Metabolic Parameters Casupporting

confidence: 77%

Effects of Weight Reduction Therapy on Obstructive Sleep Apnea Syndrome and Arterial Stiffness in Patients with Obesity and Metabolic Syndrome

Iguchi

Tochiya

Muranaka

et al. 2013

JAT

View full text Add to dashboard Cite

show abstract

“…CAVI is elevated in the patients with sleep apnea syndrome 50) and is decreased by continuous positive airway pressure treatments 75) . The abovementioned results indicated that CAVI could be a good maker of arteriosclerosis and is also a marker of arterial stiffness raised by several coronary risk factors (Table 3).…”

Section: Treatment Of Sleep Apnea Syndromementioning

confidence: 99%

The Role of a Novel Arterial Stiffness Parameter, Cardio-Ankle Vascular Index (CAVI), as a Surrogate Marker for Cardiovascular Diseases

Saiki

Sato

Watanabe

et al. 2016

JAT

View full text Add to dashboard Cite

Measurement of arterial stiffness in routine medical practice is important to assess the progression of arteriosclerosis. So far, many parameters have been proposed to quantitatively represent arterial stiffness. Among these, pulse wave velocity (PWV) has been most frequently applied to clinical medicine because those could be measured simply and non-invasively. PWV had established the usefulness of measuring arterial wall stiffness. However, PWV essentially depends on blood pressure at the time of measurement. Therefore, PWV is not appropriate as a parameter for the evaluation of arterial stiffness, particularly for the studies involving blood pressure changes.On the other hand, stiffness parameter is an index reflecting arterial stiffness without the influence of blood pressure. Recently, this parameter has been applied to develop a new arterial stiffness index called cardio-ankle vascular index (CAVI). Therefore, CAVI does not depend on blood pressure changes during the measurements; CAVI could represent the stiffness of the arterial tree from the origin of the aorta to the ankle.Many clinical studies obtained from CAVI are being accumulated. CAVI showed high value in arteriosclerotic diseases, such as coronary artery diseases, cerebral infarction, and chronic kidney diseases, and also in majority of people with various coronary risk factors. The improvement of those risk factors decreased CAVI. Furthermore, the role of CAVI as a predictor of cardio-vascular events was reported recently.We review the clinical studies on CAVI and discuss the clinical usefulness of CAVI as a candidate surrogate end-point marker for cardiovascular disease.

show abstract

“…In other words, our finding suggests that atrial conduction disturbances, which reflect AF pathogenesis, may be a modifiable target in patients with moderateto-severe OSA because the pathophysiological effects of OSA, including the mechanical and autonomic effects, can also be alleviated by CPAP therapy. 28,29 In addition, several studies have shown reductions in the levels of inflammation markers, oxidative stress markers, and matrix metalloproteinase-9 by CPAP therapy for OSA, [7][8][9]24 suggesting that CPAP therapy for OSA may blunt the progression of atrial fibrosis. Furthermore, several studies have shown a significant improvement in left ventricular diastolic function after initiation of CPAP therapy for OSA.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5][6][7][8][9] These pathophysiological effects of OSA may cause left atrial overload and remodeling, and consequently, atrial conduction disturbances that contribute to AF.…”

mentioning

confidence: 99%

Effects of Obstructive Sleep Apnea and its Treatment on Signal-Averaged P-Wave Duration in Men

Maeno

Kasagi

Ueda

et al. 2013

Circ: Arrhythmia and Electrophysiology

View full text Add to dashboard Cite

The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/doi:10.1161/CIRCEP.113.000266/-/DC1. Correspondence to Ken-ichi Maeno, MD, Sleep Center, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan, E-mail maeken@zk9.so-net.ne.jp Background-Prolonged P-wave duration, indicating atrial conduction delay, is a potent precursor of atrial fibrillation.Obstructive sleep apnea (OSA) is a risk factor for atrial fibrillation development. We investigated the association of P-wave duration with OSA and its treatment. Methods and Results-We enrolled 80 consecutive men with normal sinus rhythms who underwent polysomnography, had no history of atrial fibrillation or ischemic heart disease, and no evidence of heart failure. Signal-averaged P-wave duration (SAPWD) was measured in all participants. Multivariable regression analysis showed that age, hypertension, and log-transformed apnea-hypopnea index were significantly and independently correlated with SAPWD. SAPWD was repeatedly measured after 1 month of continuous positive airway pressure (CPAP) therapy in 62 patients with moderateto-severe OSA. As controls, 18 patients with moderate-to-severe OSA were enrolled. Their SAPWD was also measured at baseline and after 1 month without CPAP therapy. No significant change in SAPWD was found between baseline and after 1 month in the controls. However, SAPWD was significantly shortened after 1 month of CPAP therapy (from 137.5±8.6 to 129.7±8.5 ms; P<0.001), and the SAPWD change was significantly different in patients with CPAP therapy compared with controls (P<0.001). In addition, the SAPWD change in patients with CPAP therapy correlated inversely with nightly CPAP usage (r=−0.52; P<0.001). Conclusions-OSA severity was significantly associated with prolonged SAPWD. CPAP therapy significantly shortened SAPWD in patients with moderate-to-severe OSA. Thus, OSA may cause atrial conduction disturbances, leading to an increased risk of atrial fibrillation development, which may be modifiable by alleviating OSA with CPAP therapy. (Circ Arrhythm Electrophysiol. 2013;6:287-293.)

show abstract

Plasma Pentraxin3 and Arterial Stiffness in Men With Obstructive Sleep Apnea

Abstract: Plasma pentraxin3 and arterial stiffness levels in the moderate-to-severe OSA group were greater than the corresponding levels in patients without OSA. However, pentraxin3 level can be managed by CPAP therapy for OSA.

Cited by 61 publications

References 40 publications

Effects of Weight Reduction Therapy on Obstructive Sleep Apnea Syndrome and Arterial Stiffness in Patients with Obesity and Metabolic Syndrome

Effects of Weight Reduction Therapy on Obstructive Sleep Apnea Syndrome and Arterial Stiffness in Patients with Obesity and Metabolic Syndrome

The Role of a Novel Arterial Stiffness Parameter, Cardio-Ankle Vascular Index (CAVI), as a Surrogate Marker for Cardiovascular Diseases

Effects of Obstructive Sleep Apnea and its Treatment on Signal-Averaged P-Wave Duration in Men

Contact Info

Product

Resources

About